New 'Living Drug' trial targets Tough-to-Treat blood cancers
NCT ID NCT04230265
Summary
This early-stage trial tested a new type of personalized cell therapy for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to other treatments. Doctors modified patients' own immune cells (T-cells) to target a protein called CD123 found on cancer cells. The main goals were to find a safe dose and see if the treatment could help put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus University Medical Center
Rotterdam, Gelderland, 3015, Netherlands
-
Klinikum der Universität München
Munich, Bavaria, 81377, Germany
-
Philipps-Universität Marburg
Marburg, Hesse, 35032, Germany
-
Uniklinik RWTH Aachen
Aachen, North Rhine-Westphalia, 52074, Germany
-
Universitair Medisch Centrum Groningen
Groningen, GZ, 9713, Netherlands
-
Universitätsklinikum Dresden
Dresden, Saxony, 01307, Germany
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246, Germany
-
Universitätsklinikum Leipzig
Leipzig, Saxony, 04103, Germany
-
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, 89081, Germany
-
Universitätsklinikum Würzburg
Würzburg, Bavaria, 97080, Germany
Conditions
Explore the condition pages connected to this study.